AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Other Non-Cash Items · Q4 FY2024 · quarter ended Dec 2024
Other non-cash items of €333K in Q4 FY2024
Q4 FY2024 other non-cash items was €333K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
Currency unavailable · from the cash flow
No Other Non-Cash Items data reported for this period type.
Other Non-Cash Items vs competitors
How AGMB compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $78.61M USD | +42.2% | -12.8% | 33.8% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $44.46M USD | +123.1% | +1204.6% | 601.0% |
| LTM Mar 2026 | $4.76M USD | -94.7% | -21.2% | 56.9% | |
| LTM Mar 2026 | $399K USD | -97.0% | — | — | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | -26.2% | -12.8% | 56.9% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.